NCT05975463View on ClinicalTrials.gov

Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

HAIC

hepatic artery infusion for 3-4 times.

DRUG

Adebrelimab

hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.

DRUG

Bevacizumab

hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.

Trial Locations (1)

300308

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

HuiKai Li

OTHER